Smeets A, Koekoekx R, Ruelens W, Smet M, Clasen C, Van den Mooter G. Gastro-resistant encapsulation of amorphous solid dispersions containing darunavir by coaxial electrospraying. Int J Pharm. 2020;574:118885 pubmed publisher

Pastuch Gawołek G, Gillner D, Krol E, Walczak K, Wandzik I. Selected nucleos(t)ide-based prescribed drugs and their multi-target activity. Eur J Pharmacol. 2019;865:172747 pubmed publisher

Slack R, Ilina T, Xi Z, Giacobbi N, Kawai G, Parniak M, et al. Conformational Changes in HIV-1 Reverse Transcriptase that Facilitate Its Maturation. Structure. 2019;27:1581-1593.e3 pubmed publisher

Grinsztejn B, Hughes M, Ritz J, Salata R, Mugyenyi P, Hogg E, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019;6:e588-e600 pubmed publisher

Venter W, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, et al. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019;: pubmed publisher

Abreu C, Veenhuis R, Avalos C, Graham S, Queen S, Shirk E, et al. Infectious virus persists in CD4+ T cells and macrophages in ART-suppressed SIV-infected Macaques. J Virol. 2019;: pubmed publisher

Waalewijn H, Turkova A, Rakhmanina N, Cressey T, Penazzato M, Colbers A, et al. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. Ther Drug Monit. 2019;41:431-443 pubmed publisher

Hattori S, Hayashi H, Bulut H, Rao K, Nyalapatla P, Hasegawa K, et al. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. Antimicrob Agents Chemother. 2019;63: pubmed publisher

Pas T, Bergonzi A, Lescrinier E, Vergauwen B, Van den Mooter G. Drug-carrier binding and enzymatic carrier digestion in amorphous solid dispersions containing proteins as carrier. Int J Pharm. 2019;563:358-372 pubmed publisher

van Domselaar R, Njenda D, Rao R, Sonnerborg A, Singh K, Neogi U. HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness. J Virol. 2019;93: pubmed publisher

Desai J, Thakkar H. Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation. Colloids Surf B Biointerfaces. 2019;175:143-149 pubmed publisher

Daskapan A, Tran Q, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, et al. Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Ther Drug Monit. 2019;41:59-65 pubmed publisher

Ferrari D, Spagnuolo V, Manca M, Bigoloni A, Muccini C, Banfi G, et al. Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients. Antivir Ther. 2019;24:69-72 pubmed publisher

Kyei G, Meng S, Ramani R, Niu A, Lagisetti C, Webb T, et al. Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency. MBio. 2018;9: pubmed publisher

Murphy D, Desjardins D, Boyd P, Dereuddre Bosquet N, Stimmer L, Caldwell A, et al. Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques. Int J Pharm. 2018;550:300-308 pubmed publisher

Nganou Makamdop K, Billingsley J, Yaffe Z, O Connor G, Tharp G, Ransier A, et al. Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication. PLoS Pathog. 2018;14:e1007246 pubmed publisher

Pas T, Struyf A, Vergauwen B, Van den Mooter G. Ability of gelatin and BSA to stabilize the supersaturated state of poorly soluble drugs. Eur J Pharm Biopharm. 2018;131:211-223 pubmed publisher

Saag M, Benson C, Gandhi R, Hoy J, Landovitz R, Mugavero M, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320:379-396 pubmed publisher

Loelius S, Lannan K, Blumberg N, Phipps R, Spinelli S. The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res. 2018;169:96-104 pubmed publisher

Stella Ascariz N, Montejano R, Rodriguez Centeno J, Alejos B, Schwimmer C, Bernardino J, et al. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. J Infect Dis. 2018;218:1523-1530 pubmed publisher

Smeets A, Koekoekx R, Clasen C, Van den Mooter G. Amorphous solid dispersions of darunavir: Comparison between spray drying and electrospraying. Eur J Pharm Biopharm. 2018;130:96-107 pubmed publisher

Lê M, Chaix M, Chevret S, Bertrand J, Raffi F, Gallien S, et al. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018;73:2120-2128 pubmed publisher

Vadhadiya P, Jean M, Bouzriba C, Tremblay T, Lagüe P, Fortin S, et al. Diversity-Oriented Synthesis of Diol-Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor Agents. Chembiochem. 2018;: pubmed publisher

Eron J, Orkin C, Gallant J, Molina J, Negredo E, Antinori A, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32:1431-1442 pubmed publisher

Molina J, Squires K, Sax P, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e211-e220 pubmed publisher

Suvarna V, Sangave P. HPLC Estimation, Ex vivo Everted Sac Permeability and In Vivo Pharmacokinetic Studies of Darunavir. J Chromatogr Sci. 2018;56:307-316 pubmed publisher

Schalkwijk S, Buaben A, Freriksen J, Colbers A, Burger D, Greupink R, et al. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2018;57:705-716 pubmed publisher

Dock J, Hultin L, Hultin P, Elliot J, Yang O, Anton P, et al. Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes. J Immunol Methods. 2017;445:77-87 pubmed publisher

Mehmood S, Marcoux J, Gault J, Quigley A, Michaelis S, Young S, et al. Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24. Nat Chem. 2016;8:1152-1158 pubmed publisher

Cook P, Stang A, Walker L, Akula S, Cook F. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens. South Med J. 2016;109:712-717 pubmed

Taylor N, Kremser I, Auer S, Hoermann G, Greil R, Haschke Becher E, et al. Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients. J Acquir Immune Defic Syndr. 2017;75:e13-e20 pubmed publisher

Desai J, Thakkar H. Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles. J Microencapsul. 2016;33:669-678 pubmed

Venkatesh D, Baskaran M, Karri V, Mannemala S, Radhakrishna K, Goti S. Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect. Saudi Pharm J. 2015;23:667-74 pubmed publisher

Elsby R, Martin P, Surry D, Sharma P, Fenner K. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Drug Metab Dispos. 2016;44:398-408 pubmed publisher

Bernardino J, Mocroft A, Mallon P, Wallet C, Gerstoft J, Russell C, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015;2:e464-73 pubmed publisher

Birkus G, Bam R, Willkom M, Frey C, Tsai L, Stray K, et al. Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. Antimicrob Agents Chemother. 2016;60:316-22 pubmed publisher

Risher K, Rehle T, Simbayi L, Shisana O, Celentano D. Antiretroviral Treatment and Sexual Risk Behavior in South Africa. AIDS Behav. 2016;20:710-6 pubmed publisher

Inugala S, Eedara B, Sunkavalli S, Dhurke R, Kandadi P, Jukanti R, et al. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation. Eur J Pharm Sci. 2015;74:1-10 pubmed publisher

Andreatta K, Goodman D, Miller M, White K. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations. Antimicrob Agents Chemother. 2015;59:3441-9 pubmed publisher

Ofotokun I, Na L, Landovitz R, Ribaudo H, McComsey G, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842-51 pubmed publisher

Moltó J, Valle M, Ferrer E, Domingo P, Curran A, Santos J, et al. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. J Antimicrob Chemother. 2015;70:1139-45 pubmed publisher

Dubbelman A, Cuyckens F, Dillen L, Gross G, Hankemeier T, Vreeken R. Systematic evaluation of commercially available ultra-high performance liquid chromatography columns for drug metabolite profiling: optimization of chromatographic peak capacity. J Chromatogr A. 2014;1374:122-133 pubmed publisher

Jager N, Rosing H, Schellens J, Beijnen J. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 2014;6:2481-514 pubmed publisher

Del Prete G, Shoemaker R, Oswald K, Lara A, Trubey C, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother. 2014;58:6790-806 pubmed publisher

Nguyen D, Van den Mooter G. The fate of ritonavir in the presence of darunavir. Int J Pharm. 2014;475:214-26 pubmed publisher

Kakuda T, Leopold L, Timmers M, Van de Casteele T, Hillewaert V, Tomaka F, et al. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. Int J Clin Pharmacol Ther. 2014;52:805-16 pubmed

Raffi F, Babiker A, Richert L, Molina J, George E, Antinori A, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942-51 pubmed publisher

Kulkarni R, Hluhanich R, McColl D, Miller M, White K. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother. 2014;58:6145-50 pubmed publisher

Watanabe K, Varesio E, Hopfgartner G. Parallel ultra high pressure liquid chromatography-mass spectrometry for the quantification of HIV protease inhibitors using dried spot sample collection format. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:244-53 pubmed publisher

Kakuda T, Van de Casteele T, Petrovic R, Neujens M, Salih H, Opsomer M, et al. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther. 2014;19:597-606 pubmed publisher

Yu C, Campbell S, Sponseller C, Small D, Medlock M, Morgan R. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Investig. 2014;34:475-82 pubmed publisher

Loutfy M, Sherr L, Sonnenberg Schwan U, Walmsley S, Johnson M, D Arminio Monforte A. Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc. 2013;16:18509 pubmed publisher

Weber J, Rose J, Vazquez A, Winner D, Margot N, McColl D, et al. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors. PLoS ONE. 2013;8:e65631 pubmed publisher

Huhn G, Badri S, Vibhakar S, Tverdek F, Crank C, Lubelchek R, et al. Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution. AIDS Res Ther. 2010;7:44 pubmed publisher

Robertson H, Allison D. Drugs associated with more suicidal ideations are also associated with more suicide attempts. PLoS ONE. 2009;4:e7312 pubmed publisher